Loading...
Plasticity of circulating tumor cells in small cell lung cancer
Seo, J. Kumar, M. Mason, J. Blackhall, Fiona H Matsumoto, N. Hicks, J. Kuhn, P. Shishido, S. N.
Seo, J.
Kumar, M.
Mason, J.
Blackhall, Fiona H
Matsumoto, N.
Hicks, J.
Kuhn, P.
Shishido, S. N.
Citations
Altmetric:
Abstract
Small cell lung cancer (SCLC) is an aggressive neuroendocrine tumor with low five-year survival rates. Recently described molecular phenotypes of SCLC exhibit differential vulnerabilities heralding potential for stratified treatment. Whilst tumor biopsy in SCLC is challenging, circulating tumor cells in the liquid biopsy are prevalent and can be repeatedly sampled accommodating the dynamic plasticity of SCLC phenotypes. The aim of this study was to characterize the heterogeneity of rare circulating cells with confirmed tumor origin and to explore a liquid biopsy approach for future clinical trials of targeted therapies. This study applied the 3rd generation of a previously validated direct imaging platform to 14 chemo-naive SCLC patients and 10 non-cancerous normal donor (ND) samples. Phenotypic heterogeneity of circulating rare cells in SCLC was observed and a patient-level classification model was established to stratify SCLC patients from non-cancerous donors. Eight rare cell groups, with combinations of epithelial, endothelial, and mesenchymal biomarker expression patterns, were phenotypically characterized. The single-cell genomic analysis confirmed the cancer cell plasticity in every rare cell group harboring clonal genomic alterations. This study shows rare cell heterogeneity and confirms cellular plasticity in SCLC providing a valuable resource for better opportunities to discover novel therapeutic targets in SCLC.
Description
Date
2023
Publisher
Collections
Files
Keywords
Type
Article
Citation
Seo J, Kumar M, Mason J, Blackhall F, Matsumoto N, Dive C, et al. Plasticity of circulating tumor cells in small cell lung cancer. Scientific reports. 2023 Jul 21;13(1):11775. PubMed PMID: 37479829. Pubmed Central PMCID: PMC10362013 interests in Epic Sciences. P.K. is a paid consultant/advisory board member for Epic Sciences. N.M, J.H., and P.K. are royalty recipients on related technology licensed to Epic Sciences for development. All other remaining authors have no competing interest to declare. Epub 2023/07/22. eng.